These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28935264)

  • 1. A potent neuromedin U receptor 2-selective alkylated peptide.
    Nishizawa N; Kanematsu-Yamaki Y; Funata M; Nagai H; Shimizu A; Fujita H; Sakamoto J; Takekawa S; Asami T
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4626-4629. PubMed ID: 28935264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
    Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
    Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
    Kanematsu-Yamaki Y; Nishizawa N; Kaisho T; Nagai H; Mochida T; Asakawa T; Inooka H; Dote K; Fujita H; Matsumiya K; Hirabayashi H; Sakamoto J; Ohtaki T; Takekawa S; Asami T
    J Med Chem; 2017 Jul; 60(14):6089-6097. PubMed ID: 28657315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
    Masuda Y; Kumano S; Noguchi J; Sakamoto K; Inooka H; Ohtaki T
    Peptides; 2017 Aug; 94():99-105. PubMed ID: 28400225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
    Inooka H; Sakamoto K; Shinohara T; Masuda Y; Terada M; Kumano S; Yokoyama K; Noguchi J; Nishizawa N; Kamiguchi H; Fujita H; Asami T; Takekawa S; Ohtaki T
    Bioorg Med Chem; 2017 Apr; 25(8):2307-2312. PubMed ID: 28291683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.
    Ingallinella P; Peier AM; Pocai A; Marco AD; Desai K; Zytko K; Qian Y; Du X; Cellucci A; Monteagudo E; Laufer R; Bianchi E; Marsh DJ; Pessi A
    Bioorg Med Chem; 2012 Aug; 20(15):4751-9. PubMed ID: 22771182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
    Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
    Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
    Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
    Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
    Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
    J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromedin U receptor 1 expression in the rat endocrine pancreas and evidence suggesting neuromedin U suppressive effect on insulin secretion from isolated rat pancreatic islets.
    Kaczmarek P; Malendowicz LK; Pruszynska-Oszmalek E; Wojciechowicz T; Szczepankiewicz D; Szkudelski T; Nowak KW
    Int J Mol Med; 2006 Nov; 18(5):951-5. PubMed ID: 17016626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of peripherally administered neuromedin U on energy and glucose homeostasis.
    Peier AM; Desai K; Hubert J; Du X; Yang L; Qian Y; Kosinski JR; Metzger JM; Pocai A; Nawrocki AR; Langdon RB; Marsh DJ
    Endocrinology; 2011 Jul; 152(7):2644-54. PubMed ID: 21586559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and expression patterns of neuromedin U and its receptors in pigs.
    Li X; Niu M; Su J; Ma Z; Jin M; Qiao W; Zhang Y; Feng Y; An N; Hou Y; Yang S; Chuan S; Lei Z
    Neuropeptides; 2017 Aug; 64():47-60. PubMed ID: 28434792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent and proteolytically stable human neuromedin U receptor agonists.
    De Prins A; Martin C; Van Wanseele Y; Skov LJ; Tömböly C; Tourwé D; Caveliers V; Van Eeckhaut A; Holst B; Rosenkilde MM; Smolders I; Ballet S
    Eur J Med Chem; 2018 Jan; 144():887-897. PubMed ID: 29329072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of neuromedin U type 1 receptor inhibits L-type Ca2+ channel currents via phosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway in mouse hippocampal neurons.
    Zhang Y; Jiang D; Zhang J; Wang F; Jiang X; Tao J
    Cell Signal; 2010 Nov; 22(11):1660-8. PubMed ID: 20599609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of neuromedin U (NMU), neuromedin S (NMS) and their receptors (NMUR1, NMUR2) in chickens.
    Wan Y; Zhang J; Fang C; Chen J; Li J; Li J; Wu C; Wang Y
    Peptides; 2018 Mar; 101():69-81. PubMed ID: 29288685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chemically stable peptide agonist to neuromedin U receptor type 2.
    Takayama K; Mori K; Tanaka A; Sasaki Y; Sohma Y; Taguchi A; Taniguchi A; Sakane T; Yamamoto A; Miyazato M; Minamino N; Kangawa K; Hayashi Y
    Bioorg Med Chem; 2020 May; 28(10):115454. PubMed ID: 32247748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The discovery of neuromedin U and its pivotal role in the central regulation of energy homeostasis].
    Kirsz K; Zięba DA
    Postepy Hig Med Dosw (Online); 2012 Apr; 66():196-203. PubMed ID: 22706104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two chicken neuromedin U receptors: characterization of primary structure, biological activity and tissue distribution.
    Yamamoto I; Nakao N; Kaiya H; Miyazato M; Tsushima N; Arai T; Tanaka M
    Gen Comp Endocrinol; 2011 Nov; 174(2):116-23. PubMed ID: 21878335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromedin U receptor 2 knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat food and leads to increased body weight.
    Benzon CR; Johnson SB; McCue DL; Li D; Green TA; Hommel JD
    Neuroscience; 2014 Jan; 258():270-9. PubMed ID: 24269937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.
    Takayama K; Mori K; Taketa K; Taguchi A; Yakushiji F; Minamino N; Miyazato M; Kangawa K; Hayashi Y
    J Med Chem; 2014 Aug; 57(15):6583-93. PubMed ID: 24999562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.